TMExplore™
The TMExplore™ is a unique tissue-based approach combining different technologies perfectly adapted to the comprehensive characterization of the tumor microenvironment.
As a main pillar of this approach, HalioDx proposes Immunoscore® for Clinical research based on our strong scientific Bedrock on Immunoscore® in colon cancer.
These assays allows to identify precise cell populations, observe gene expression profiling and focus on biomarkers spatial analysis via Brightplex® multiplex IHC technologies. Our ultimate goal is to deliver to biopharma meaningful insights, gain knowledge in drug mechanism of action and its impact on the immune contexture of the tumor.
Data can be combined into an Immunogram, a multimodal analysis, providing a 360° view of the tumor microenvironment.
Our expertise: Immunoscore® for Clinical Research (CR)
Leverage HalioDx know how acquired with Immunoscore®, to propose an enhanced next generation Immunoscore® with multiplex and spatially resolved capabilities for clinical investigations.
- Robust immunohistochemistry assays using standardized reagents
- Classify tumors in hot/cold, exhausted/ not exhausted and immunosuppressed/not immunosuppressed
- Flexible multiplexing capabilities
- Deliver spatially resolved phenotypic imaging data
- Validated in several cancer types
All of our solutions are customizable to include your biomarker of interest and build your own Immunoscore® with a growing range of immune phenotypes available.
Resources on IMMUNOSCORE® CR
#publication | août. 2020
Bruni D, K Angell H and Galon J
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
Nature Reviews Cancer
#video | juin. 2020
Webinar: Exploring Changes of Myeloid Cells with Chromogenic Multiplex IHC in Advanced Liver Cancer| Prof. Nagy Habibi & Jacques Fieschi, PhD
#video | mai. 2020
Webinar: Capturing the Complexity of the Tumor Microenvironment | Jérôme Galon, PhD & Jacques Fieschi, PhD
#video | nov.. 2019
Webinar: Evaluating Biomarkers During Clinical Trials for Immunotherapies. A Case Study on the Pioneer Project
#poster | nov.. 2019
Poster presented at ESMO 2019 by Transgene
In the Phase Ib/II trial of TG4001, HalioDx Immunoscore®, Immunosign® and others clinical research service have been performed to assess Immune contexture of patients.
#poster | nov.. 2019
Poster presented at SITC 2019
Tumor Infiltrating Lymphocytes (TILs) in triple-negative breast cancer: High Immunoscore is associated with pathological CR in patients receiving neoadjuvant chemotherapy.
#poster | nov.. 2019
Poster presented at ESMO 2019
High Immunoscore® is associated with good response to neo-adjuvant chemotherapy and prolonged survival in advanced Head and Neck cancer patients.
#publication | août. 2019
Angell HK, Bruni D, Barrett JC et al.
The Immunoscore: Colon Cancer and Beyond.
Clin Cancer Res.
#publication | juil.. 2019
Mascaux C, Angelova M, Vasaturo A et al.
Immune evasion before tumour invasion in early lung squamous carcinogenesis.
Nature
#video | juil.. 2019
HalioDX is part of the COLOSSUS project by performing Immunoscore and help stratification of difficult to treat mCRC patients with a final objective to Improve their management and treatment
#video | juin. 2019
Jérôme Galon, winner for the European Inventor Award 2019 for Immunoscore®
#publication | mai. 2019
Pages F, Andre T, Taieb J et al.
Validation of the Immunoscore prognostic value in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR)
Journal of Clinical Oncology
#publication | mai. 2019
Galon J & Bruni D
Tumor Immunology and Tumor Evolution: Intertwined Histories
Immunity
#publication | mars. 2019
Zeitoun G, Sissy CE, Kirilovsky A et al.
The Immunoscore in the Clinical Practice of Patients with Colon and Rectal Cancers.
Chirurgia (Bucur).
#brochure | mars. 2019
Brochure Clinical Research
HalioDx Biopharma Services
#publication | mars. 2019
Galon J & Bruni D
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies.
Nat Rev Drug Discov.
#publication | oct.. 2018
Angelova M, Mlecnik B, Vasaturo A et al.
Evolution of Metastases in Space and Time under Immune Selection.
Cell
#poster | oct.. 2018
Poster presented at the CRI-CIMT-EATI-AACR 2018
T cell exhaustion assessment using an automated sequential chromogenic multiplex assay (Brightplex®)
#publication | déc.. 2017
Fridman WH, Zitvogel L, Sautès-Fridman C, Kroemer G
The immune contexture in cancer prognosis and treatment.
Nat Rev Clin Oncol.
#poster | sept.. 2017
Poster presented at NSH 2017
A multiplex immunohistochemistry assay for immune cells profiling on whole FFPE tumor tissue sections
#publication | févr.. 2016
Mlecnik B, Bindea G, Kirilovsky A et al.
The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis.
Sci Transl Med.
#publication | juin. 2015
Berghoff AS, Fuchs E, Ricken G et al.
Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases.
Oncoimmunology
#publication | oct.. 2013
Bindea G, Mlecnik B, Tosolini M et al.
Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.
Immunity
#publication | juil.. 2013
Galon J, Angell HK, Bedognetti D, Marincola FM
The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures.
Immunity
#publication | mars. 2012
Fridman WH, Pagès F, Sautès-Fridman C, Galon J.
The immune contexture in human tumours: impact on clinical outcome.
Nat Rev Cancer.